Colgate Rallies After Earnings as Analysts Lift Targets

Colgate-Palmolive enters the post-earnings week with the Street in an unusually unified mood, nearly every major firm raising its price target after the October 30 print delivered a 4.6% single-day gain.

The analyst response after Q3 results was broad and largely constructive. Morgan Stanley lifted its target to $111 from $104, maintaining Overweight, while UBS moved to $112 from $106 on a Buy. BNP Paribas raised to $108 from $97 on Outperform, and BofA Securities went to $105 from $100, also on Buy. RBC Capital nudged its Outperform target to $105. The dissenters were few: JPMorgan actually trimmed its target slightly to $102 from $104 while holding Overweight, and both Barclays and Wells Fargo moved their Equal-Weight targets to $95, right at the current price. The mean target now sits at $101.70 against a close of $95.62, implying modest upside but nothing that screams rerate. The PE multiple has expanded to 23.5x over the past month as the stock climbed 13.5%, and price-to-book is a full 96.8x, reflecting the brand premium investors have consistently been willing to pay. Factor scores are mixed: the dividend rank sits in the 97th percentile, forward EPS growth ranks 72nd, but analyst recommendation divergence scores just 7th, meaning the consensus is unusually tight rather than a broad upgrade cycle.

Positioning in the lending market remains entirely uncontentious for a $76 billion consumer staples name. Borrow availability stands at over 3,200% of short interest, meaning the pool of shares available to lend dwarfs the positions already borrowed by a wide margin. Cost to borrow has fallen sharply, down 44% on the week to 0.30%, its lowest reading in the 30-day window. Short interest itself is 2.2% of the free float, a level the previous note correctly described as low. Notably, SI dropped materially in late October from around 3% to its current level, coinciding with the earnings beat, suggesting some short covering followed the print. The options market has also shifted. The pre-earnings put/call ratio of 0.86, flagged in the prior note as defensively elevated, has eased only slightly to 0.877, still running 1.5 standard deviations above the 20-day average of 0.796. That is a less alarmed reading than the week before, but it still sits above what would be considered neutral for this name.

Peers broadly moved in the same direction on the week, though with notable variation on the day. CHD gained 3.95% over five days and CLX added 7.4%, outpacing Colgate's 3.7% weekly move. KMB was the exception, giving back 4.3% on the week and falling a further 3.5% on Tuesday alone, suggesting that the strong earnings reception was stock-specific rather than a wholesale sector rerate. PG added 1.8% on the week, a more muted response. CL's one-day decline of 1.9% on November 3 came despite the positive week, tracking a mild pullback across the group.

The alt data layer offers one supporting colour point. SEC EDGAR filings show Colgate's buyback spend in Q2 2026 came in at $291 million, up 25% on the same quarter a year earlier. No dataset in the coverage universe has been measured to lead the company's reported figures, so the buyback figure is best read as a capital allocation signal rather than a revenue pointer.

The next earnings date is January 29, 2027, giving the market 86 days to decide whether the post-Q3 target upgrades hold at current price levels or whether the still-elevated put/call ratio reflects lingering unease about raw material costs and Hill's brand volume trends that the bull case has not yet fully resolved.